Related Experiment Videos
Rapamycin, a potential disease-modifying antiarthritic drug
R P Carlson1, D A Hartman, L A Tomchek
1Wyeth-Ayerst Research, Princeton, New Jersey.
The Journal of Pharmacology and Experimental Therapeutics
|August 1, 1993
Summary
Rapamycin (RAPA) effectively treats T cell-mediated inflammation and arthritis in animal models, with lasting effects after dosing stops. This immunosuppressive drug shows potential for treating autoimmune diseases like rheumatoid arthritis and multiple sclerosis.
Area of Science:
- Immunology
- Pharmacology
- Rheumatology
Background:
- Rapamycin (RAPA) is a potent immunosuppressive agent used in transplantation.
- Its mechanism of action differs from cyclosporin A and FK-506.
- The study investigates RAPA's potential as an antiarthritic agent.
Purpose of the Study:
- To assess the pharmacological activity of RAPA in immune and inflammatory models.
- To define RAPA's potential utility in treating autoimmune and inflammatory conditions.
Main Methods:
- Evaluated RAPA's efficacy in mouse delayed-type hypersensitivity model.
- Assessed RAPA's effects on developing and established adjuvant arthritis in rats.
- Tested RAPA in experimental allergic encephalomyelitis and carrageenan paw edema models.
- Investigated RAPA's in vitro effects on phospholipase A2, 5-lipoxygenase, and cyclo-oxygenase.
Main Results:
- RAPA inhibited T cell-mediated inflammation and arthritis in animal models.
- RA PA's anti-inflammatory effects persisted after drug cessation, unlike cyclosporin A.
- Higher doses of RAPA reduced acute inflammation without elevating corticosterone.
- RAPA did not inhibit key inflammatory enzymes in vitro.
Conclusions:
- RAPA demonstrates significant anti-inflammatory and immunosuppressive properties.
- Its sustained efficacy in T cell-mediated models suggests potential for autoimmune diseases.
- RA PA may be a valuable therapeutic agent for rheumatoid arthritis, multiple sclerosis, and other autoimmune conditions.